Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haemodynamic Effects of Dobutamine in Patients with Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)
2023-508298-10-00Phase 2Authorised
- Sponsor
- Central Denmark Region
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dobutamine in wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) and heart failure (HF), sponsored by Central Denmark Region. Primary endpoint: Change in cardiac output (CO). Planned start Dec 2023; status: authorised.
02
Drugs
dobutamine
03
Conditions
wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM)heart failure (HF)
Beyond the preview
Go deeper on 2023-508298-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508298-10-00.